The Preeclampsia Foundation and AMAG Pharmaceuticals, Inc. today announced a Corporate Partnership focused on the ongoing commitment of both organizations to improve the diagnosis and treatment of hypertensive disorders of pregnancy, including preeclampsia, eclampsia, and HELLP syndrome.
“We appreciate AMAG Pharmaceuticals’ support of our efforts as a Corporate Partner,” said Eleni Tsigas, Chief Executive Officer of the Preeclampsia Foundation. “AMAG Pharmaceuticals has been a long-time supporter of the Foundation, and we value their ongoing commitment to incorporating patient insights into research and development efforts.
“AMAG is committed to maternal health, including serving patients with preeclampsia, a serious pregnancy complication that threatens the lives of mothers and babies, which makes finding treatment options a dire unmet need,” said Julie Krop, M.D., chief medical officer and executive vice president of development at AMAG. “We are very proud to support the work of The Preeclampsia Foundation in their tireless mission to improve diagnosis, management and prevention of preeclampsia through research and improved healthcare practices.”
As a Corporate Partner, AMAG enables the Preeclampsia Foundation to fulfill its mission as a leading authority and influencer in the areas of research, healthcare practices, and community engagement for the hypertensive disorders of pregnancy by:
- representing the patient voice in the development and execution of research studies related to maternal and infant mortality and morbidity, in particular preeclampsia and the other hypertensive disorders of pregnancy
- providing the patient perspective as quality improvement has become a touchstone issue for improving maternal and infant outcomes
- gathering and sharing the wide and deep perspective of the patient experience with the affected community, those providing care, and those researching a cause and a cure
The Preeclampsia Foundation’s Corporate Partner program is open to organizations with a shared mission of saving the lives of moms and babies from the potentially devastating impact of preeclampsia and other hypertensive disorders of pregnancy.
For information on how to become a Corporate Partner with the Preeclampsia Foundation, contact Chris McGahee, Director of Development, at 321-421-6957 or email@example.com.
About the Preeclampsia Foundation
The Preeclampsia Foundation is a U.S.-based 501(c)(3) non-profit organization established in 2000. It is dedicated to providing patient support and education, raising public awareness, catalyzing research, and improving healthcare practices, envisioning a world where preeclampsia and related hypertensive disorders of pregnancy no longer threaten the lives of mothers and babies. For more information, visit www.preeclampsia.org.
AMAG is a pharmaceutical company focused on bringing innovative products to patients with unmet medical needs. The company does this by leveraging its development and commercial expertise to invest in and grow its pharmaceutical products across a range of therapeutic areas, including women’s health. For additional company information, please visit www.amagpharma.com.